PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress
Hayes C, Gallucci G, Boyer J, Assis D, Ghonem N. PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress. Hepatology Communications 2024, 9: e0612. PMID: 39699308, PMCID: PMC11661771, DOI: 10.1097/hc9.0000000000000612.Peer-Reviewed Original ResearchConceptsPeroxisome proliferator-activated receptor agonistsPrimary biliary cholangitisPrimary sclerosing cholangitisPeroxisome proliferator-activated receptorUnited States Food and Drug Administration approvalHepatic accumulation of bile acidsRisk of progression to cirrhosisFood and Drug Administration approvalPeroxisome proliferator-activator receptor agonismSecond-line therapyFirst-line therapySymptoms of cholestasisDrug Administration approvalTreatment of cholestatic liver diseasesCholestatic liver diseaseAccumulation of bile acidsProgression to cirrhosisTreatment of cholestasisSignificant clinical interestSmall bile ductsProliferator-activated receptorsBile acid metabolismIncomplete respondersBiliary cholangitisBiliary strictures
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply